Statins

Episode 5: Statin Intolerance in Focus: Navigating Side Effects, Patient Concerns, and the Path to Optimal LDL Lowering

When two past NLA Presidents and seasoned podcast hosts sit down together, the conversation is bound to be something special.…

The Lipid Panel – Statins and Intracerebral Hemorrhage

Managing the Statin-Intolerant Patient: Low-Dose/Low-Frequency Treatment Regimens

Statin clinical trials suggest an incidence of adverse muscular events of ~ 1.5 – 3%, but the true incidence of…

Tolerability of Statin Therapy in Children

Regardless of the low number of children who will require treatment, obstacles remain for these pediatric patients. Medications commonly associated…

Statins in Chronic Kidney Disease and Dialysis: Clinical Trials, Mechanisms, Dosing, and Treatment Recommendations

Patients with chronic kidney disease (CKD) including those undergoing dialysis have an increased risk of premature cardiovascular disease (CVD). CKD…

Case Study: Statin Use in the Elderly: An Age-Old Question

Many physicians are faced with a growing elderly population in their practice and the resulting therapeutic dilemmas. A 10- year…

My Statin or My Sarcolemma? Could Vitamin D Provide Some Answers for Improved Statin Compliance?

Data from the Cholesterol and Recurrent Events (CARE), Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), and Scandinavian Simvastatin Survival…

Age-Related Pharmacokinetic Changes and the Impact on Statin Therapy in Older Patients

While there is evidence for atherosclerotic cardiovascular risk reduction with statins in both primary and secondary prevention in older patients,…

The Use of Statins to Reduce Cardiovascular Risk in the Elderly

There is compelling and consistent evidence from clinical outcome trials that reducing the level of LDL-C with statins reduces the…

Management of Statin Treatment in Adult Solid Organ Transplant Recipients

Solid organ transplantation (SOT), encompassing kidney, liver, heart and to a lesser extent pancreas and lung, has become routine care…

Statins and Brain Fog: Confusing for Patients, Prescribers, and Me

HMG-CoA reductase inhibitors (statins) were FDA-approved in 1987 and their introduction has revolutionized lipid and cardiovascular (CV) management for the…

NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient

NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant…

Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association

Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association

S3E2: Statin Underuse Persistence

Alan S. Brown, MD, FACC, MNLA talks with Mary Katherine Cheeley, PharmD, CLS, FNLA about the persistence of statin underuse…

Dietary Supplements or Statins for LDL-C Lowering

More than half of adults in the United States report taking dietary supplements. For example, some choose supplements in place…

Case Study: Incident Type 2 Diabetes Mellitus following Statin Initiation in Youth

The association of statin use, and incident type 2 diabetes (T2D) is well established in adults. Similar observations have not…

Lipid Management in Pregnancy and Lactation

Normal pregnancy is characterized by physiologic increases in maternal levels of cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein…

Managing Hypercholesterolemia in Adults Older Than 75 Years Without a History of Atherosclerotic Cardiovascular Disease: An Expert Clinical Consensus from the National Lipid Association and the American Geriatrics Society

Managing Hypercholesterolemia in Adults Older Than 75 Years Without a History of Atherosclerotic Cardiovascular Disease: An Expert Clinical Consensus from…

LDL Cholesterol Management Simplified in Adults—Lower for Longer is Better: Guidance from the National Lipid Association

LDL cholesterol management simplified in adults—lower for longer is better: Guidance from the National Lipid Association

Episode 4: Pharmacotherapy Development and Trends in Lipidology: An Expert Discussion

In this compelling episode of NLA Industry Innovations, guest host Kevin Maki, PhD, CLS, MNLA sits down with renowned lipidologist and clinical…

Case Study: Pharmacotherapy for Dyslipidemia and Metabolic Dysfunction-Associated Steatotic Fatty Liver Disease

Clinical Case The patient is a 67-year-old white gentleman with type 2 diabetes mellitus (T2DM), hypertension (HTN), 20-pack-year smoking history,…

Differences in Statin Metabolism in East Asians

Elevated plasma levels of low-density lipoprotein cholesterol (LDL-C) play a significant role in the development of Coronary Artery Disease (CAD).(1)…

Tools for Alleviating Drug Disparities in Lipidology

The armamentarium for lipid-lowering pharmacotherapy is evolving. Though statins remain the cornerstone of treatment, and nearly all statins and ezetimibe…

Women’s Health: Guidelines for Lipid-Lowering in Women – What Have we Learned?

Cardiovascular disease (CVD) remains the leading cause of death for women in the United States.(1) Unique factors affecting a woman’s…

Lipid Metabolism and Cardiovascular Disease in Patients with Renal Disease

Reduced estimated glomerular filtration rate (GFR) and chronic kidney disease (CKD) are also independently associated with the risk of death…

Statin Use in Chronic Hepatitis C Infection, NAFLD/NASH, Cirrhosis and Hepatocellular Carcinoma

Case Presentation: G.S. is a 60-year-old male referred for cholesterol treatment complicated by background liver disease. He has a history…

Statins for Primary Prevention in Women: How an Individual-Benefit Model Could Expand Treatment to Hypercholesterolemic Women Under Age 65 with 10-Year ASCVD Risk Less Than 7.5%

Evidence in support of statins for the primary prevention of atherosclerotic cardiovascular disease (ASCVD) in women was sparse until recently.1 …

Effects of Post-Transplant Drugs on Lipids and Treatment Options

EpidemiologyThe ever- increasing population of patients living after organ transplantation has added an important dimension to the specific management needs…